Literature DB >> 17118341

CD133+ hepatic stellate cells are progenitor cells.

Claus Kordes1, Iris Sawitza, Alexis Müller-Marbach, Niloofar Ale-Agha, Verena Keitel, Hanne Klonowski-Stumpe, Dieter Häussinger.   

Abstract

Hepatic stellate cells (HSC) play an important role in the development of liver fibrosis. Here, we report that HSC express the stem/progenitor cell marker CD133 and exhibit properties of progenitor cells. CD133+ HSC of rats were selected by specific antibodies and magnetic cell sorting. Selected cells displayed typical markers of HSC, endothelial progenitor cells (EPC), and monocytes. In cell culture, CD133+ HSC transformed into alpha-smooth muscle actin positive myofibroblast-like cells, whereas application of cytokines known to facilitate EPC differentiation into endothelial cells led to the formation of branched tube-like structures and induced expression of the endothelial cell markers endothelial nitric oxide synthase and vascular-endothelial cadherin. Moreover, cytokines that guide stem cells to develop hepatocytes led to the appearance of rotund cells and expression of the hepatocyte markers alpha-fetoprotein and albumin. It is concluded that CD133+ HSC are a not yet recognized progenitor cell compartment with characteristics of early EPC. Their potential to differentiate into endothelial or hepatocyte lineages suggests important functions of CD133+ HSC during liver regeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118341     DOI: 10.1016/j.bbrc.2006.11.029

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  89 in total

Review 1.  Liver progenitor cells-mediated liver regeneration in liver cirrhosis.

Authors:  Haitao Shang; Zhijun Wang; Yuhu Song
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

Review 2.  Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Authors:  Pooja Chaudhari; Lipeng Tian; Abhijeet Deshmukh; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy.

Authors:  M Swiderska-Syn; W K Syn; G Xie; L Krüger; M V Machado; G Karaca; G A Michelotti; S S Choi; R T Premont; A M Diehl
Journal:  Gut       Date:  2013-10-30       Impact factor: 23.059

5.  Convenient and efficient enrichment of the CD133+ liver cells from rat fetal liver cells as a source of liver stem/progenitor cells.

Authors:  Wei-hui Liu; Ren Li; Ke-feng Dou
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 6.  Earlier and broader roles of Mesp1 in cardiovascular development.

Authors:  Yu Liu
Journal:  Cell Mol Life Sci       Date:  2017-01-03       Impact factor: 9.261

Review 7.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 8.  [Liver fibrosis - pathogenesis and novel therapeutic approaches].

Authors:  F Tacke; R Weiskirchen
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

9.  Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells.

Authors:  Lin Cui; Kenoki Ohuchida; Kazuhiro Mizumoto; Taiki Moriyama; Manabu Onimaru; Kohei Nakata; Toshinaga Nabae; Takashi Ueki; Norihiro Sato; Yohei Tominaga; Masao Tanaka
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

10.  Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.

Authors:  Kouichi Tabu; Taichi Kimura; Ken Sasai; Lei Wang; Norihisa Bizen; Hiroshi Nishihara; Tetsuya Taga; Shinya Tanaka
Journal:  Mol Cancer       Date:  2010-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.